<PAGE> 1
FORM 10-Q
---------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 1997
--------------
OR
( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
For the transition period from _______ to ______
Commission file number 0-26872
GELTEX PHARMACEUTICALS, INC.
----------------------------
(Exact name of registrant as specified in its charter)
Delaware 04-313676
------------------------------- ---------------------------------
(State or other jurisdiction of (IRS Employer Identification No.)
incorporation or organization)
303 Bear Hill Road
Waltham, Massachusetts 02154
---------------------------------------- ---------------------------------
(Address of principal executive offices) (Zip Code)
617-290-5888
-------------------------------
(Registrant's telephone number,
including area code)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes X No
--- ---
The number of shares outstanding of each of the issuer's classes of common stock
as of the latest practicable date:
Class Outstanding at April 30, 1997
----- -----------------------------
Common Stock, $.01 par value 13,538,002
THIS IS PAGE 1 OF 41 PAGES. THE EXHIBIT INDEX IS ON PAGE 11.
<PAGE> 2
GELTEX PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
<TABLE>
TABLE OF CONTENTS
<CAPTION>
Page No.
--------
<S> <C> <C>
PART I FINANCIAL INFORMATION
ITEM 1 Financial Statements
Condensed Balance Sheets as of March 31, 1997 and December
31, 1996.................................................. 3
Condensed Statements of Operations for the three months
ended March 31, 1997 and 1996, and for the period from
November 15, 1991 (date of inception) through March 31,
1997...................................................... 4
Condensed Statements of Cash Flows for the three months
ended March 31, 1997 and 1996, and for the period from
November 15, 1991 (date of inception) through March 31,
1997...................................................... 5
Notes to Condensed Financial Statements................... 6
ITEM 2 Management's Discussion and Analysis of Financial
Condition and Results of Operations....................... 7
PART II OTHER INFORMATION
ITEM 5 Other Information......................................... 9
ITEM 6 Exhibits and Reports on Form 8-K.......................... 9
SIGNATURES................................................................. 10
EXHIBIT INDEX.............................................................. 11
</TABLE>
-2-
<PAGE> 3
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
GELTEX PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
<TABLE>
CONDENSED BALANCE SHEETS
(UNAUDITED)
<CAPTION>
March 31, December 31,
1997 1996
------------ ------------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents ............................................................ $ 15,567,088 $ 20,801,465
Marketable securities ................................................................ 52,597,014 52,623,094
Prepaid expenses and other current assets .......................................... 1,341,513 1,923,878
------------ ------------
Total current assets ................................................................... 69,505,615 75,348,437
Long-term receivables .................................................................. 20,000 20,000
Property and equipment, net ............................................................ 1,992,201 2,246,910
Intangible assets, net ................................................................. 516,372 453,123
------------ ------------
$ 72,034,188 $ 78,068,470
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Account payable and accrued expenses ................................................. $ 2,332,313 $ 2,495,869
Current portion of capital lease obligations ......................................... 300,404 391,766
------------ ------------
Total current liabilities .............................................................. 2,632,717 2,887,635
Long-term obligations, less current portion ............................................ 319,393 124,360
Stockholders' equity:
Undesignated Preferred Stock, $.01 par value; 5,000,000 shares
authorized, none issued or outstanding ......................................... -- --
Common Stock, $.01 par value, 50,000,000
shares authorized; 13,532,302 and 13,521,302 shares issued
and outstanding at March 31, 1997 and December 31, 1996,
respectively ................................................................... 135,323 135,213
Additional paid-in capital ........................................................... 106,012,689 105,407,670
Deferred compensation ................................................................ (576,193) (46,129)
Deficit accumulated during the development stage ..................................... (36,417,926) (30,460,246)
Unrealized gain (loss) on available-for-sale securities .............................. (71,815) 19,967
------------ ------------
Total stockholders' equity ............................................................. 69,082,078 75,056,475
------------ ------------
$ 72,034,188 $ 78,068,470
============ ============
</TABLE>
The accompanying notes are an integral part of the financial statements.
-3-
<PAGE> 4
GELTEX PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
<TABLE>
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)
<CAPTION>
For the Period
November 15,
Three Months 1991 (date
Ended March 31, of inception)
------------------------------------- through
1997 1996 March 31, 1997
---- ---- ---------------
<S> <C> <C> <C>
Revenue:
License fee and research revenue ............................ $ -- $ -- $ 4,994,474
Research grant .............................................. 139,642 149,822 715,593
----------- ----------- ------------
Total revenue .................................................. 139,642 149,822 5,710,067
Costs and expenses:
Research and development .................................... 6,144,043 2,564,563 39,149,783
General and administrative .................................. 908,747 568,533 7,885,371
Other, nonrecurring costs ................................... -- -- 230,000
----------- ----------- ------------
Total costs and expenses ....................................... 7,052,790 3,133,096 47,265,154
----------- ----------- ------------
Loss from operations ........................................... (6,913,148) (2,983,274) (41,555,087)
Interest income ................................................ 966,021 371,637 5,373,644
Interest expense ............................................... (10,553) (22,151) (236,483)
----------- ----------- ------------
Net loss ....................................................... $(5,957,680) $(2,633,788) $(36,417,926)
=========== =========== ============
Net loss per share ............................................. $ (.44) $ (.25)
=========== ===========
Shares used in computing
net loss per share .......................................... 13,524,000 10,575,000
</TABLE>
The accompanying notes are an integral part of the financial statements
-4-
<PAGE> 5
GELTEX PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
<TABLE>
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
<CAPTION>
For the Period
November 15,
Three Months 1991 (date
Ended March 31, of inception)
------------------------------------ through
1997 1996 March 31, 1997
------ ------ ---------------
<S> <C> <C> <C>
OPERATING ACTIVITIES
Net loss ............................................................ $ (5,957,679) $ (2,633,788) $ (36,417,925)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization ................................... 742,236 229,477 2,408,510
Issuance of Common Stock as compensation ........................ -- -- 5,000
Changes in operating assets and liabilities:
Prepaid expenses and other current assets ..................... 582,364 (115,321) (1,341,514)
Long-term receivables ......................................... -- -- (20,000)
Accounts payable and accrued expenses ......................... (163,844) (857,626) 2,332,025
------------ ------------ -------------
Net cash used in operating activities ............................... (4,796,923) (3,377,258) (33,033,904)
INVESTING ACTIVITIES
Purchase of marketable securities ................................... (40,426,066) (2,040,120) (161,999,651)
Proceeds from sale and maturities of
marketable securities ............................................. 40,360,365 992,890 109,330,823
Purchase of intangible assets ....................................... (63,249) (63,675) (800,836)
Purchase of property and equipment, net ............................. (423,103) (199,792) (3,026,364)
------------ ------------ -------------
Net cash used in investing activities ............................... (552,053) (1,310,697) (56,496,028)
FINANCING ACTIVITIES
Sale of Common Stock and warrants, net of
issuance costs .................................................... 10,928 4,195 87,689,252
Proceeds from employee stock purchase plan .......................... -- -- 113,993
Sale of Preferred Stock, net of issuance costs ...................... -- -- 17,480,688
Proceeds from lease financing of assets ............................. 245,944 -- 980,944
Payments on notes payable and capital lease obligations ............. (142,273) (130,847) (1,167,857)
------------ ------------ -------------
Net cash provided by (used in) financing activities ................. 114,599 (126,652) 105,097,020
------------ ------------ -------------
Increase (decrease) in cash and cash equivalents .................... (5,234,377) (4,814,607) 15,567,088
Cash and cash equivalents at beginning of period .................... 20,801,465 12,179,988 --
------------ ------------ -------------
Cash and cash equivalents at end of period .......................... $ 15,567,088 $ 7,365,381 $ 15,567,088
============ ============ =============
Schedule of noncash investing and financing activities:
Property and equipment acquired under capital leases ............ $ 1,110,000
</TABLE>
The accompanying notes are an integral part of the financial statements
-5-
<PAGE> 6
GELTEX PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
1. BASIS OF PRESENTATION
The accompanying unaudited condensed financial statements for the three
months ended March 31, 1997 and 1996 and for the period November 15, 1991 (date
of inception) through March 31, 1997 have been prepared in accordance with
generally accepted accounting principles for interim financial information and
with the instructions to Form 10-Q and Article 10 of Regulation S-X.
Accordingly, they do not include all the information and footnotes required by
generally accepted accounting principles for complete financial statements. In
the opinion of management, the accompanying condensed financial statements
include all adjustments, consisting of normal recurring accruals, necessary for
a fair presentation of the financial condition, results of operations and cash
flows for the periods presented. The results of operations for the interim
period ended March 31, 1997 are not necessarily indicative of the results to be
expected for the year ended December 31, 1997.
These financial statements should be read in conjunction with the
audited financial statements and notes thereto for the fiscal year ended
December 31, 1996 included in the Company's Annual Report on Form 10-K (File
Number 0-26872) as filed with the Securities and Exchange Commission.
2. NET LOSS PER SHARE
In February, 1997, the Financial Accounting Standards Board issued
Statement No. 128, "Earnings per Share," which is required to be adopted on
December 31, 1997. At that time, the Company will be required to change the
method currently used to compute earnings per share and to restate all prior
periods. Under the new requirements for calculating basic earnings per share,
the dilutive effect of stock options will be excluded. The impact is not
expected to result in a change in basic loss per share for the first quarter
ended March 31, 1997 or in the basic loss per share for the first quarter ended
March 31, 1996. The impact of Statement 128 on the calculation of fully diluted
earnings per share for these quarters is not expected to be material.
-6-
<PAGE> 7
GELTEX PHARMACEUTICALS, INC
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
RESULTS OF OPERATIONS
THREE MONTHS ENDED MARCH 31, 1997 AND 1996
The Company earned revenues of $140,000 during the three months ended
March 31, 1997 compared with $150,000 earned during the three months ended March
31, 1996. In both periods, revenue was earned under the Company's $2.0 million
grant from the United States Department of Commerce's Advanced Technology
Program.
The Company's total operating expenses for the three months ended March
31, 1997 were $7.1 million, as compared to $3.1 million during the three months
ended March 31, 1996. Research and development expenses increased to $6.1
million for the three months ended March 31, 1997 from $2.6 million for the
three months ended March 31, 1996 due primarily to increased third party
expenses associated with the development of CholestaGel(R) non-absorbed
cholesterol reducer and RenaGel(R) non-absorbed phosphate binder (including
production of clinical trial material, clinical trial expenses and process
development expenses) and increases in research and development personnel costs.
General and administrative expenses increased to $909,000 for the three months
ended March 31, 1997 from $569,000 for the three months ended March 31, 1996 due
primarily to increased business development expenses and increased
administrative personnel.
Interest income increased to $966,000 for the three months ended March
31, 1997 from $372,000 for the three months ended March 31, 1996 due primarily
to increases in cash balances attributable to the Company's sale of equity
securities through a public offering in May 1996.
-7-
<PAGE> 8
LIQUIDITY AND CAPITAL RESOURCES
As of March 31, 1997, the Company had $68.2 million in cash, cash
equivalents and marketable securities as compared to $73.4 million at
December 31, 1996.
At March 31, 1997, the Company had approximately $245,000 outstanding
and $755,000 available through December 18, 1997, on a $1.0 million equipment
line of credit with a bank and had an additional $236,000 outstanding on various
other lines of credit with the bank. All amounts outstanding bear interest at
the prime rate and are due in monthly installments through July 1999.
In April, 1997, the Company entered into a contract manufacturing
agreement for RenaGel. Under the terms of the agreement, the Company is required
to fund capital equipment costs of approximtely $6.0 million. The Company may be
obligated to pay up to $3.75 million in additional equipment costs in the event
that the Company requires the manufacturer to increase capacity and implement
certain manufacturing changes designed to result in a lower product cost to the
Company. The Company may seek third party financing for the capital equipment
costs. The contract manufacturing agreement also requires the Company to
purchase minimum quantities of product beginning in 1998. The minimums are based
upon the Company's estimated product requirements and are subject to increases
as product sales increase and as the manufacturer increases its capacity for the
product. The Company's minimum purchase obligation will be approximately $5.5
million in 1998.
In connection with the execution of the contract manufacturing agreement,
the Company became obligated to make a one-time $1.5 million royalty payment to
a third party for a license to certain process development technology developed
by the third party under contract to the Company.
-8-
<PAGE> 9
PART II OTHER INFORMATION
ITEM 5. OTHER INFORMATION
The Company plans to its accelerate the commencement of Phase III
clinical trials for a capsule formulation of CholestaGel(R) non-absorbed
cholesterol reducer in lieu of conducting a Phase II clinical trial with a 650
mg tablet formulation. The Company expects to commence Phase III trials of the
capsule formulation in the third quarter of 1997 and will continue work on
perfecting a tablet formulation of CholestaGel(R).
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits.
See the Exhibit Index on page 11 hereto.
(b) Reports on Form 8-K.
None.
-9-
<PAGE> 10
GELTEX PHARMACEUTICALS, INC.
FORM 10-Q
MARCH 31, 1997
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
GELTEX PHARMACEUTICALS, INC.
DATE: May 14, 1997 BY: /s/ Paul J. Mellett, Jr.
----------------------------
Paul J. Mellett, Jr.
Duly Authorized Officer and
Principal Financial Officer
-10-
<PAGE> 11
EXHIBIT INDEX
Exhibit Number Description Page
- -------------- ----------- ----
10.17* Contract Manufacturing Agreement between 12
the Company and The Dow Chemical
Company
27 Financial Data Schedule
(filed with electronic submission only)
- ----------------------
* Certain confidential material contained in Exhibit 10.17 has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Act of 1934.
-11-
<PAGE> 1
* Certain Confidential material contained in Exhibit 10.17 has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 the Securities Act of 1934, as amended.
EXHIBIT 10.17
CONTRACT MANUFACTURING AGREEMENT
BETWEEN
THE DOW CHEMICAL COMPANY
AND
GELTEX PHARMACEUTICALS, INC.
<PAGE> 2
TABLE OF CONTENTS
Page
----
ARTICLE 1 - DEFINITIONS........................................1
ARTICLE 2 - PURPOSE............................................4
ARTICLE 3 - TERM...............................................5
ARTICLE 4 - QUALITY............................................5
ARTICLE 5 - QUANTITIES.........................................5
ARTICLE 6 - PRICES FOR PRODUCT.................................9
ARTICLE 7 - DELIVERY, TITLE, TRANSPORTATION....................10
ARTICLE 8 - INVOICES AND PAYMENT...............................10
ARTICLE 9 - WARRANTIES AND OBLIGATIONS OF CUSTOMER.............11
ARTICLE 10 - LIMITED WARRANTY...................................11
ARTICLE 11 - DISCLAIMER OF WARRANTIES...........................11
ARTICLE 12 - INSPECTION AND NOTICE OF CLAIMS....................11
ARTICLE 13 - LIMITATION OF REMEDIES AND LIABILITY...............12
ARTICLE 14 - INTELLECTUAL PROPERTY..............................12
ARTICLE 15 - INDEMNITY..........................................14
ARTICLE 16 - INSURANCE..........................................15
ARTICLE 17 - DOW FACILITY.......................................16
ARTICLE 18 - PRODUCT STEWARDSHIP................................16
ARTICLE 19 - FORCE MAJEURE......................................17
ARTICLE 20 - EARLY TERMINATION..................................18
ARTICLE 21 - ASSIGNMENT.........................................18
ARTICLE 22 - NOTICE.............................................18
ARTICLE 23 - PLANT VISITS.......................................19
-i-
<PAGE> 3
TABLE OF CONTENTS
(CONTINUED)
Page
----
ARTICLE 24 - CONFIDENTIALITY OF INFORMATION....................19
ARTICLE 25 - EXPORT CONTROL OF TECHNICAL DATA..................21
ARTICLE 26 - TAXES.............................................21
ARTICLE 27 - INDEPENDENT CONTRACTOR............................21
ARTICLE 28 - SEVERABILITY......................................21
ARTICLE 29 - NON-WAIVER OF DEFAULTS............................22
ARTICLE 30 - CREDIT............................................22
ARTICLE 31 - GOVERNING LAW.....................................22
ARTICLE 32 - HEADINGS..........................................22
ARTICLE 33 - ENTIRE AGREEMENT..................................22
ARTICLE 34 - ARBITRATION.......................................23
SCHEDULE 1 PRODUCT SPECIFICATIONS
SCHEDULE 2 OPERATING GUIDELINES
SCHEDULE 3 VISITORS AGREEMENT
-ii-
<PAGE> 4
CONTRACT MANUFACTURING AGREEMENT
This Contract Manufacturing Agreement, effective April 21, 1997 (the "Effective
Date"), is between THE DOW CHEMICAL COMPANY, a Delaware corporation ("DOW"), and
GELTEX PHARMACEUTICALS, INC., a Delaware corporation ("CUSTOMER"). In
consideration of the mutual covenants set forth in this Agreement, DOW and
CUSTOMER agree as follows:
ARTICLE 1 - DEFINITIONS
- -----------------------
"AFFILIATE" as used in this Agreement with respect to one party, means any
company controlling, controlled by or under common control with such party. For
the purpose of this definition, a company shall be deemed to control another
company when it owns, directly or indirectly, more than 50% of the voting stock
of (or similar interest in) the latter.
"AGREEMENT" means this Contract Manufacturing Agreement, as may be amended from
time to time according to Article 33, and any Schedules to this Agreement. The
terms and conditions of this Agreement shall control over any terms and
conditions included in documents used by CUSTOMER to order Product, or by DOW in
accepting or confirming orders. Any term or condition on a purchase order,
acceptance or any other document which is not in accordance with this Agreement
is invalid.
"ANALYTICAL INFORMATION" means technology and data developed and owned or
possessed by CUSTOMER for the manufacture of Product ** * ********** *******
******* *** ******* ** ******** **** *** ********* ***** ** ** ************
******* *** **** ******** **** *** ******** which technology and data formally
shall be transferred to Dow in a manner that (a) meets FDA requirements and (b)
can be used by Dow to manufacture Product.
"CALENDAR YEAR" means a twelve (12) month period commencing January 1.
"CERCLA" means the Federal Comprehensive Environmental Response, Compensation
and Liability Act, 42 U.S.C. 6901 et seq.
"CLAIM(S)" means any legal or equitable causes of action (including but not
limited to negligence; strict liability; other tort; express or implied
warranty, indemnity or contract; contribution; or subrogation) related to or
arising out of the performance or nonperformance of this Agreement.
"DOW FACILITY" means DOW's multi-purpose manufacturing facility located in
Midland, Michigan.
* Confidential Treatment Requested for information omitted and filed separately
with the SEC.
-1-
<PAGE> 5
"DOW KNOW-HOW" means DOW's proprietary business and technical information
concerning products and the processes used to manufacture products, including,
but not limited to: (a) production forecasts; (b) product, raw material,
packaging and equipment specifications and samples; (c) process and
manufacturing information consisting of descriptions, NDAs and other pertinent
documents concerning methods, formulae and standards for the manufacture of
products; (d) quality control information and data; (e) analytical procedures
and data; and (f) performance test data.
"EFFECTIVE DATE" means the date stated above.
"FDA" means the United States Food and Drug Administration.
"FDCA" means the Federal Food, Drug and Cosmetic Act, 21 U.S.C. ss.ss.301 ET
SEQ.
"FORCE MAJEURE EVENT" means any event beyond the reasonable control of the party
affected which significantly interferes with the production, supply,
transportation, consumption or Waste disposal practice of the party at the time
respecting the Product covered by this Agreement, or the inability to obtain on
terms reasonably deemed by DOW to be practicable any supplies, parts or raw
material (including energy or other utilities) used in connection therewith,
such as any accident, mechanical breakdown of facilities, fire, flood, strike,
labor trouble, riot, revolt, war, drought, inability to meet governmental
environmental waste disposal standards, action of governmental authority and
laws, rules, ordinances and regulations (including, but not limited to, those
dealing with pollution, health, ecology, or environmental matters), acts of God,
or other similar types of contingencies.
"GMPS" means current Good Manufacturing Practices as defined in FFDCA and
related regulations.
"IND(S)" means an Investigational New Drug as defined in FFDCA and related
regulations.
"KG" means kilograms.
"MONTH(S)" means a calendar month commencing on the first day of a month.
"MT" means metric tons.
"NDA(S)" means a New Drug Application as defined in FFDCA and related
regulations.
********* ***** ***** ****** **** ***** * ******** ********
-2-
* Confidential Treatment Requested for information omitted and filed separately
with the SEC.
<PAGE> 6
"OPERATING GUIDELINES" means a description of the process for the manufacture of
the Product as contained in the Chemical Methods Control section of the NDA, all
as set forth in Schedule 2. The Operating Guidelines may be amended from time to
time upon the mutual written agreement of DOW and CUSTOMER.
***** ***** ************** ************* *** ******* ******** ** * ****** *****
** ***** ***** ** **** ********* **** ********
"PRICE" means the charge for the contract manufacturing of the Product in United
States dollars as calculated in Article 6.
"PRICE INDEX" means the CMR Market Index as announced by the Chemical Marketing
Reporter for the applicable Calendar Year.
"PRODUCT" means sevelamer hydrochloride, which is a bulk non-systemic drug
substance used to lower phosphate levels in dialysis patients, manufactured by
DOW for CUSTOMER. Over time the parties may agree to add additional items to the
Product list according to Section 5.4.
"PROFESSIONAL" means a DOW employee or contractor who has obtained a minimum of
a bachelor's degree in a scientific or technically related field and who
performs services pursuant to this Agreement. For the purpose of this Agreement,
a Professional shall not include a person who performs routine maintenance or
normal quality assurance and quality control duties.
"PROPRIETARY INFORMATION" means confidential information disclosed or developed
pursuant to the terms of this Agreement.
"QUARTER" means three consecutive Months commencing January 1, April 1, July 1
or October 1.
"RCRA" means the Federal Resource Conservation and Recovery Act, 42 U.S.C. 6901
et seq.
"RESEARCH SERVICE AGREEMENT" means the Research Service Agreement dated
September 1, 1996, as amended, between DOW and CUSTOMER.
"SPECIFICATION(S)" means the agreed-to specifications for the Product as fully
described in Schedule 1. The Specifications may be amended from time to time
upon the mutual written agreement of DOW and CUSTOMER.
"WASTE(S)" means "hazardous substance which is disposed or released" as defined
in CERCLA, and "waste" as defined in RCRA and includes waste of any kind
including, without limitation, both routine process waste and by-products which
are disposed.
-3-
* Confidential Treatment Requested for information omitted and filed separately
with the SEC.
<PAGE> 7
"WORK DAY" means each day of the week excluding Saturday, Sunday and any public
holiday.
ARTICLE 2 - PURPOSE
- ---------------------
2.1 DOW agrees to manufacture and sell Product to CUSTOMER and CUSTOMER agrees
to purchase and receive Product from DOW, pursuant to the terms and conditions
stated in this Agreement. DOW's manufacturing responsibilities are:
(a) unloading, handling and storing raw materials and packaging
materials at the DOW Facility;
(b) manufacturing Product;
(c) collecting and retaining for three (3) years lot samples of the
Product;
(d) packaging Product;
(e) handling and storing bulk and packaged Product;
(f) preparing Product for shipment;
(g) making the Product available to a common carrier;
(h) keeping records and reporting to CUSTOMER and applicable
governmental agencies;
(i) handling, storing, treating, and disposing of Wastes generated by
DOW in DOW's performance of this Agreement; and
(j) compliance with all applicable laws and regulations regarding the
manufacture of the Product, including, but limited to, current GMPs.
2.2 CUSTOMER recognizes and agrees that the ability of DOW to manufacture
Product pursuant to this Agreement depends upon a continuous supply to DOW of
**** Based upon this requirement, CUSTOMER shall obtain a license from *******
and shall provide or make available to DOW a steady supply of *** sufficient for
the manufacture of the quantity of Products requested by CUSTOMER.
-4-
* Confidential Treatment Requested for information omitted and filed separately
with the SEC.
<PAGE> 8
ARTICLE 3 - TERM
- ------------------
3.1 The term of this Agreement is for an initial term from the Effective Date
until December 31, 2002. Thereafter, this Agreement automatically shall continue
for successive periods of one (1) year unless terminated by at least twelve (12)
months' prior written notice of one party to the other.
3.2 DOW may terminate the sales of the Product to CUSTOMER, and CUSTOMER may
terminate the obligation to purchase the Product from DOW, at any time after
December 31, 2001, by giving at least one (1) year prior written notice of
termination to the other party. Any such termination properly notified shall be
effective on December 31, 2002 or on December 31 of any succeeding Calendar
Year.
3.3 Anything in this Agreement to the contrary notwithstanding, this Agreement
shall terminate upon the failure of CUSTOMER to provide for a continuous supply
of *** for a period of sixty (60) days pursuant to Section 2.2 in sufficient
quantities for the manufacture of Product.
ARTICLE 4 - QUALITY
- ---------------------
4.1 The manufacturing process for the Product shall conform to the process set
forth in the Operating Guidelines.
4.2 DOW shall test or cause to be tested each batch of Product as specified in
the Specifications before shipment to CUSTOMER or its designee for compliance
with the Specifications. The completeness and accuracy of the Specifications are
solely CUSTOMER's responsibility. DOW shall retain a sample of each batch tested
for three (3) years from the date of shipment; however, CUSTOMER is responsible
for retaining CUSTOMER's own samples for FDA purposes. For each batch shipped,
DOW shall prepare a certificate of analysis setting forth the items tested, the
Specifications and test results and forward the certificates to CUSTOMER, or its
designee, at the time the Product is shipped.
4.3 DOW shall label the Product as specified by CUSTOMER. CUSTOMER shall procure
all registrations, permits and licenses with respect to packaging, labeling and
Specification of the Product and use of the Product at CUSTOMER's expense.
Without limiting the forgoing, CUSTOMER shall file with the FDA, in CUSTOMER's
own name, all INDs and NDAs required for Product.
ARTICLE 5 - QUANTITIES
- ------------------------
5.1 (a) Upon obtaining the capability to manufacture Product, and subject to the
provisions of Section 5.1(b), Dow shall maintain a manufacturing capacity level
at the DOW Facility of ***** **** ****** **** for the manufacture of Product.
-5-
* Confidential Treatment Requested for information omitted and filed separately
with the SEC.
<PAGE> 9
(b) DOW shall construct the DOW Facility. In addition, DOW and CUSTOMER
mutually shall agree upon the timing of any needed capacity expansion, and DOW
shall execute a project to expand the manufacturing capacity of the DOW Facility
upon receipt of written notice from CUSTOMER of any needed capacity expansion.
DOW shall use reasonable efforts to complete such capacity expansion in the time
frame reasonably agreed between DOW and CUSTOMER. Subject to the provisions set
forth below in this Section 5.1(b), CUSTOMER shall incur all capital costs for
the initial construction within the DOW Facility and for any expansions to the
manufacturing capacity of the DOW Facility for the manufacture of Product up to
***** **** ** capacity for Product. DOW shall be responsible for capital costs
for capacity expansion above ***** **** ** at the DOW Facility. The capacity
maximums at the DOW Facility, minimum purchase obligations of CUSTOMER based on
capacity expansions, and capital requirements to CUSTOMER for construction and
expansion of the DOW Facility, shall be as follows:
DOW Facility Capacity Expansions
Dow Facility Minimum Purchase Capital
Capacity Capacity Maximum Obligation Expenditure
-------- ---------------- ---------- -----------
Initial Capacity ** * ** ** ** ** $6.00 MM
** ** ******** ** ** ** ** $0.75 MM
*** ********** ** ** ** ** $2.00 MM
****** ********** ($3.00 MM)
** ** Increase *** ** ** ** --(3)
TOTAL $8.75 MM
($9.75 MM)
(1) The capital charges in this instance assume successful completion of the
research projects in the Research Service Agreement described in Section
6.1(b).
(2) The capital charges in this instance assume successful completion of the
research projects in the Research Service Agreement described in Section
6.1(c).
(3) Dow will be responsible for capital expenditures to increase the maximum
capacity of the DOW Facility above a capacity maximum of ** ** ** ** *
up to a capacity maximum of *** ***
DOW and CUSTOMER understand and agree that the capital expenditures described in
this Section 5.1 are subject to * *********** ******* ***** ******** *** *
****** ******* ***** ********* *** *** ******* ** *** ***** ****** If the
capital requirements
-6-
* Confidential Treatment Requested for information deleted and filed separately
with the SEC.
<PAGE> 10
for the construction and expansion of the DOW Facility exceed ***********
******* ***** ** *** ********* ******* *********** ********* ** *** *****
******* **** *** ***** **** **** ****** ***** ** ** ***** ******* ***** *****
*** ********* ******* ************ *********** *** *** ******** ***** **** ****
****** ***** ********
DOW and CUSTOMER further understand and agree that the capital expenditures set
forth in the table above in this Section 5.1(b) are required in order to
purchase equipment to be used by DOW to satisfy its obligations to CUSTOMER for
the manufacture of Product under this Agreement. DOW shall not incur any costs
for which CUSTOMER will be required to make a capital expenditure without the
prior written consent of CUSTOMER. DOW and CUSTOMER mutually will agree on the
project scope and the list of major equipment to be purchased. All equipment
purchased by DOW on behalf of CUSTOMER and charged to CUSTOMER as a capital
expenditure will be leased by CUSTOMER to Dow in accordance with the terms of an
equipment lease between CUSTOMER and DOW and dated as of the Effective Date.
5.2 (a) During 1998, DOW and CUSTOMER agree that the minimum amount of Product
that CUSTOMER is obligated to purchase from DOW is ****** **** ** and that the
maximum amount of Product that DOW is obligated to supply to CUSTOMER is *****
**** ***
(b) DOW and CUSTOMER agree that the annual minimum amount of Product which
CUSTOMER is obligated to purchase from DOW during each Calendar Year during the
term of this Agreement shall be the higher of the minimum purchase obligation
defined in Section 5.1(b) and ****** ******* ***** ** *** ****** ******
************ ** ******* ** ********* PROVIDED, HOWEVER, that DOW shall not be
obligated to supply more than the maximum amount of Product defined in Section
5.1(b). When the forecasts provided pursuant to Section 5.3(a) indicate that the
maximum amount of Product CUSTOMER reasonably anticipates it will purchase
during a Calendar Year exceeds *** ******* ***** *** DOW and CUSTOMER will meet
and determine how to supply the Product requirements of CUSTOMER, provided that
DOW has the right of first refusal, to be exercised within ninety (90) days,
whether to supply all or a portion of such additional quantities of Products.
(c) The maximum amount of Product which DOW is obligated to supply shall
not exceed the manufacturing capability of the DOW Facility as defined in
Section 5.1(a), as that amount may be increased pursuant to Section 5.1(b).
(d) If CUSTOMER does not take the minimum amount of Product as determined
for each Calendar Year, then CUSTOMER shall be obligated to pay to DOW an amount
as if CUSTOMER had purchased from DOW the annual minimum Product quantity for
that Calendar Year.
-7-
* Confidential Treatment Requested for information omitted and filed separately
with the SEC.
<PAGE> 11
(e) If, during any Calendar Year during the term of this Agreement, DOW and
CUSTOMER cannot agree on the annual minimum amounts of Product which CUSTOMER is
obligated to purchase from DOW or the annual maximum amounts of Product which
DOW is obligated to supply to CUSTOMER, then the annual minimum and maximum
amounts of Product for that Calendar Year shall be equal to the minimum and
maximum amounts of Product in the immediately preceding Calendar Year.
5.3 (a) CUSTOMER shall use reasonable commercial efforts to purchase Product
evenly during the course of any given Calendar Year during the term of this
Agreement. To this end, forty-five (45) days prior to each Quarter, CUSTOMER
shall provide a non-binding written forecast to DOW stating the amount of the
Product CUSTOMER reasonably anticipates it will purchase from DOW for each of
the next eight Quarters broken out by Month.
(b) Firm purchase orders for Product shall be placed by CUSTOMER within
five (5) business days of the end of the Month preceding the Month in which
CUSTOMER expects shipment of the Product. The firm purchase orders may differ
from the forecast provided by CUSTOMER; PROVIDED, HOWEVER, that DOW shall not be
obligated to supply CUSTOMER in any given Month amounts of Product in excess of
one hundred fifteen percent (115%) of the amount provided for such Month in the
most recent Quarterly forecast provided by CUSTOMER.
(c) Each firm purchase order shall include (i) the quantity of Product to
be purchased; (ii) the requested delivery date(s) therefore; (iii) any relevant
shipping instructions; and (iv) any other information dictated by the
circumstances of the order. DOW shall accept purchase orders issued to it by
CUSTOMER that are within the amounts allowed by the restrictions set forth in
5.2(b) and 5.3(b) above within five (5) days after receipt of such purchase
order. DOW shall use commercially reasonable efforts to ship product to CUSTOMER
in accordance with the terms of the purchase order.
5.4 The parties recognize that detailed and continuing exchanges of information
shall be necessary in order to optimize the administration of this Agreement and
DOW's sale of Product to CUSTOMER, consistent with their respective rights and
responsibilities under this Agreement. To that end, each party shall notify the
other of the individual representative or representatives responsible for
exchanging information and for resolving issues which arise affecting the
production of Product by DOW for sale to CUSTOMER. The designated
representatives of CUSTOMER and DOW shall conduct a planning meeting at least
once per month to address issues which shall arise under this Agreement,
including allowing DOW the ability to efficiently meet CUSTOMER's purchase
needs. Other topics of discussion between the parties may include DOW
manufacturing, selling and delivering products in addition to the Product to
CUSTOMER under an amendment to this Agreement or under separate terms and
conditions to be mutually agreed upon by the parties.
-8-
<PAGE> 12
ARTICLE 6 - PRICES FOR PRODUCT
- --------------------------------
6.1 Subject always to the payment obligations of CUSTOMER for Product contained
in Section 5.2(d), Product pricing, based on the volume of Products purchased
during a Calendar Year, shall be as follows:
(a) INITIAL PRODUCT PRICING. Assuming acceptance by the FDA of the process
described in the Operating Guidelines, Product pricing shall be:
Amount (MT) Price ($/Kg)
----------- ------------
** ** ** ***
** * ** ***
** * ** ***
**** ** ***
(b) PRODUCT PRICING BASED ON ************ ********. Assuming (i) successful
implementation of the process described in the Operating Guidelines, (ii)
successful implementation of ************ ******** *** ******* at volumes
greater than ***** **** ** per year as described in the amendment to the
Research Service Agreement dated as of the Effective Date, and (iii) acceptance
by the FDA of the processes described in this Section 6.1(b), Product pricing
shall be:
Amount (MT) Price ($/Kg)
----------- ------------
** ** ** ***
** * ** ***
** * ** ***
** * ** ***
**** ** ***
(c) PRODUCT PRICING BASED ON ***** ****. Assuming (i) the manufacturing
process at the DOW Facility can be optimized as described in the amendment to
the Research Service Agreement dated as of the Effective Date, (ii) successful
implementation of the procedures described in Section 6.1(b)(ii), and (iii)
acceptance by the FDA of the processes described in this Section 6.1(c), Product
pricing shall be:
Amount (MT) Price ($/Kg)
----------- ------------
** ** ** ***
** * ** ***
** * ** ***
** * ** ***
**** ** ***
* Confidential Treatment Requested for information omitted and filed separately
with the SEC.
-9-
<PAGE> 13
The Product pricing in Sections 6.1(a), 6.1(b) and 6.1(c) assumes a *** purchase
price of ****** per Kg. If *** pricing is different, then the Product pricing
will be adjusted accordingly.
6.2 (a) Subject always to the payment obligations of CUSTOMER for Product
contained in Section 5.2(d), and except as otherwise provided in Section 6.1,
DOW and CUSTOMER shall agree on the price for Product in each Calendar Year
during the term of this Agreement. If, during any Calendar Year during the term
of this Agreement, DOW and CUSTOMER cannot agree on Product pricing, then the
Product pricing for the Calendar Year in question shall equal the Product
pricing for the immediately preceding Calendar Year.
(b) Product pricing for each Calendar Year during the term of this
Agreement shall be adjusted based on the Price Index.
6.3 If CUSTOMER terminates the Product per Section 3.2, then CUSTOMER shall be
obligated to purchase Product, or pay the equivalent amount for Product as
determined pursuant to Section 5.2(d), up to and including the date on which the
termination takes effect, unless otherwise mutually agreed upon by the parties.
If DOW terminates the Product per Section 3.2, then CUSTOMER shall pay for
Product actually taken up to and including the date of termination, but shall
not be responsible for any amounts pursuant to Section 5.2(d).
ARTICLE 7 - DELIVERY, TITLE, TRANSPORTATION
- ---------------------------------------------
7.1 Title to, and risk of loss for, Product shall transfer to CUSTOMER upon
delivery by DOW to a common carrier acceptable to DOW and CUSTOMER.
7.2 Product shall be shipped in mutually acceptable types and sizes of packaging
or other shipping containers. The method of shipment shall be by a mutually
agreed common carrier. CUSTOMER will pay all freight, which shall be invoiced
separately to CUSTOMER. Emergency response for any emergencies or other
incidents occurring during transit shall be the responsibility of CUSTOMER.
ARTICLE 8 - INVOICES AND PAYMENT
- ----------------------------------
8.1 DOW shall issue a monthly invoice itemizing the Price on a
Product-by-Product basis for Product shipped during the preceding Month. Prices
shall be based on estimated purchases of Product by CUSTOMER during each
Calendar Year. Within fifteen (15) business days after the end of each Calendar
Year, DOW shall determine the actual amount of Product purchased by CUSTOMER
during such Calendar Year, and issue an invoice or credit to CUSTOMER based on
pricing for the actual amount of Product purchased. Any credit issued to
CUSTOMER that is not fully utilized within six (6) Months shall be refunded
promptly to CUSTOMER.
* Confidential Treatment Requested for information omitted and filed separately
with the SEC.
-10-
<PAGE> 14
8.2 Payment terms are net thirty (30) days from date of invoice. Payments past
due bear interest calculated per annum from the due date to the date of actual
payment at a fluctuating interest rate equal at all times to the prime rate of
interest announced publicly from time to time by Morgan Guaranty Trust Company
of New York, plus two percent (2%), but in no case higher than the maximum rate
permitted by applicable law.
ARTICLE 9 - WARRANTIES AND OBLIGATIONS OF CUSTOMER
- ---------------------------------------------------
9.1 Prior to the supply of Product under this Agreement, CUSTOMER shall enter
into a joint marketing or other similar arrangement with a pharmaceutical
company of established reputation.
9.2 CUSTOMER warrants that, with regard to the Product, it shall, and shall
cause any pharmaceutical company with which it associates in the
commercialization of the Product to, comply with all applicable laws, including
but not limited to the FFDCA and rules and regulations promulgated by the FDA.
ARTICLE 10 - LIMITED WARRANTY
- -------------------------------
SUBJECT TO THE LIMITATIONS OF ARTICLES 11, 12, AND 13, DOW warrants that, at the
time of delivery, the Product supplied by DOW shall (a) meet the Specification
for the Product; (b) be conveyed with good title, free from any lawful security
interest, lien or encumbrance; (c) be manufactured in compliance with the
Operating Guidelines; (d) be manufactured in accordance with current GMPs; and
(e) not be adulterated or misbranded within the meaning of the FFDCA; provided,
however, DOW shall not be liable for misbranding which is due to any labeling,
instructions or package insert text provided to DOW by CUSTOMER.
ARTICLE 11 - DISCLAIMER OF WARRANTIES
- ---------------------------------------
THE LIMITED WARRANTIES CONTAINED IN ARTICLE 10 OF THIS AGREEMENT ARE THE SOLE
WARRANTIES WITH RESPECT TO THE PRODUCT AND ARE MADE EXPRESSLY IN LIEU OF AND
EXCLUDE ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR
PURPOSE AND ALL OTHER EXPRESS OR IMPLIED REPRESENTATIONS AND WARRANTIES PROVIDED
BY COMMON LAW OR STATUTE.
ARTICLE 12 - INSPECTION AND NOTICE OF CLAIMS
- ----------------------------------------------
Promptly upon receipt of each batch of Product, CUSTOMER shall inspect, analyze
and test the Product for any damage, defect or shortage and promptly shall
notify Dow whether Product conforms to Specifications. EXCEPT WHERE DOW HAS
PROVIDED WARRANTIES UNDER THIS AGREEMENT, ALL CLAIMS BY CUSTOMER SHALL BE DEEMED
WAIVED UNLESS MADE BY CUSTOMER IN WRITING AND RECEIVED BY DOW WITHIN SIXTY (60)
DAYS OF THE RECEIPT OF THE PRODUCT PROVIDED THAT FOR ANY CLAIM WHICH IS NOT
READILY DISCOVERABLE WITHIN SUCH 60-DAY PERIOD SUCH CLAIM SHALL BE DEEMED WAIVED
UNLESS MADE BY CUSTOMER IN
-11-
<PAGE> 15
WRITING AND RECEIVED BY DOW WITHIN THREE HUNDRED SIXTY (360) DAYS AFTER RECEIPT
OF THE PRODUCT OR WITHIN THIRTY (30) DAYS AFTER CUSTOMER LEARNS OR SHOULD HAVE
BEEN REASONABLY AWARE OF FACTS WHICH SHOULD HAVE GIVEN RISE TO SUCH CLAIM,
WHICHEVER FIRST OCCURS.
ARTICLE 13 - LIMITATION OF REMEDIES AND LIABILITY
- ---------------------------------------------------
13.1 EXCEPT AS TO SECTION 15.1 AND SECTION 14.4, CUSTOMER'S EXCLUSIVE REMEDY AND
DOW'S TOTAL LIABILITY TO CUSTOMER FOR CLAIMS FOR PRODUCT DELIVERED UNDER THIS
AGREEMENT IS EXPRESSLY LIMITED AS FOLLOWS: ******** *** *** ****** **
*********** **, ** ********* ** *** ***** **** ***, *** ******* **** ******* **
***** ******* *** *******. CUSTOMER WAIVES ALL OTHER CLAIMS BY CUSTOMER AGAINST
DOW FOR PRODUCT DELIVERED UNDER THIS AGREEMENT.
13.2 NEITHER DOW NOR CUSTOMER SHALL BE UNDER ANY LIABILITY TO CUSTOMER FOR ANY
INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES.
13.3 The provisions of this Article 13 shall survive any termination of this
Agreement.
ARTICLE 14 - INTELLECTUAL PROPERTY
- ------------------------------------
14.1 DOW Know-How is owned by DOW. CUSTOMER will provide DOW with Analytical
Information concerning the manufacture and packaging of the Products. Analytical
Information is owned by CUSTOMER. CUSTOMER grants to DOW a non-exclusive,
non-transferable, royalty-free license to use Analytical Information in order to
manufacture Product.
14.2 CUSTOMER will provide DOW with reasonable access to knowledgeable people to
consult with DOW on the implementation of Analytical Information. Such
consultations shall be free of charge and shall occur at mutually agreeable
times and places (either at the DOW Facility or a facility owned and/or operated
by CUSTOMER).
14.3 CUSTOMER warrants either (a) there is no patent or copyright covering any
Product or the Analytical Information used by DOW to produce Product or (b)
CUSTOMER has a right to have Product made by DOW, and to have DOW use the
Analytical Information used to produce Product. CUSTOMER assumes all
responsibility for use of any design, trademark, trade name, copyright or part
thereof, appearing on the
* Confidential Treatment Requested for information omitted and filed separately
with the SEC.
-12-
<PAGE> 16
Product at CUSTOMER's request. CUSTOMER will *********, ****** *** **** ********
*** **** *** ******* *** *** *** ***** *** ******** ********** **********
*********' **** ******** **** ****** ***** ** *** *************** *** **********
** ******** ** **** ******* ****.
14.4 DOW warrants that it has the right to use DOW Know-How to produce Product.
DOW will *********, ****** *** **** ******** *** **** *** ******* *** *** ***
***** *** ******** ********** ********** *********' **** ******** **** ******
***** ** *** *************** *** ********** ** ******** ** **** ******* ****.
14.5 DOW and CUSTOMER recognize that detailed information, including but not
limited to Analytical Information and DOW Know-How, must be exchanged in order
to optimize the administration of this Agreement and the manufacture and sale of
Product by DOW to CUSTOMER, consistent with the respective rights and
obligations of DOW and CUSTOMER under this Agreement. Each party shall deliver
to the other such information as expeditiously as possible in order to
manufacture Product in the quantities defined in Article 5.
14.6 DOW shall retain all right, title and interest in, and CUSTOMER shall have
no right to, DOW Know-How (except pursuant to the Research Service Agreement)
and in any software, hardware, firmware and other information management and
control systems, including, without limitation, business, research and
manufacturing control and information management systems (such as computers,
computer programs and other computer related technology), and information,
plans, technical data, ideas, discoveries, works of authorship, patentable and
unpatentable inventions, know-how, process improvements, procedures,
specifications, engineering drawings, equipment, packaging etc. that relate to
software, hardware, firmware and other information management and control
systems, resulting from DOW's efforts under this Agreement.
14.7 DOW and CUSTOMER agree that any development work defined in the Research
Service Agreement shall be performed pursuant to, and governed by, the Research
Service Agreement.
14.8 Any improvements, technology or other know-how developed by DOW outside of
the provisions of the Research Service Agreement (including, but not limited to,
improvements, technology or other know-how developed by DOW in the course of
manufacturing Products under this Agreement) shall be owned by DOW and shall not
be subject to the terms and conditions of the Research Service Agreement.
14.9 The provisions of this Article 14 shall survive termination of this
Agreement and shall be interpreted to conform to the provisions of the Research
Service Agreement.
* Confidential Treatment Requested for information omitted and filed separately
with the SEC.
-13-
<PAGE> 17
ARTICLE 15 - INDEMNITY
- ------------------------
15.1 DOW shall indemnify, defend and hold CUSTOMER harmless from and against any
and all liabilities, claims, demands, damages, costs, expenses or money
judgments (including attorneys' fees) incurred by, or rendered against, CUSTOMER
arising out of *** ****** ** *** *********** ** ****** ** ******* ********* **
*** *** ******** ** * ********/******** ****** ** *** *** *** ******** ** ******
********* ** *** ** ********** **** ***** *********** ** **** *********
provided, however, CUSTOMER shall give DOW notice in writing as soon as
practicable of any such claim or lawsuit and shall permit DOW to undertake the
defense thereof at DOW's expense. For purposes of this Section 15.1,
"liabilities, claims, demands, damages, costs, expenses or money judgments"
shall include assertions involving federal, state and local laws, regulations
and ordinances, including, but not limited to, ****** *** ****, or comparable
and applicable state statutes. DOW has no obligation to indemnify CUSTOMER
(including under common law) except as specifically set forth in this Section
15.1 and as provided in Section ****.
15.2 CUSTOMER shall cooperate in any defense DOW undertakes pursuant to Section
15.1 by providing access to witnesses and evidence available to CUSTOMER.
CUSTOMER shall have the right to participate in any defense to the extent that,
in its judgment, CUSTOMER may be prejudiced thereby.
15.3 In any claim or suit in which CUSTOMER seeks indemnification by DOW,
CUSTOMER shall not settle, offer to settle or admit liability or damages in any
such claim or suit without the consent of DOW.
15.4 Inasmuch as DOW shall be manufacturing Product pursuant to Specifications
provided by CUSTOMER, except as specifically set forth in Section 15.1, ********
***** ** *********** *** *** *** *** ******** ****** ** ******** ******
********** ****** **** ****** ** *** ******* ** *** ********* **** **
*********** *** ******* ** *** *** ******** ***** **** *********. CUSTOMER
shall, and shall use best efforts to, cause any pharmaceutical company with
which it associates in the commercialization of the Product to, indemnify,
defend and hold DOW harmless from and against any and all liabilities, claims,
demands, damages, costs, expenses or money judgments (including attorneys' fees)
incurred by or rendered against DOW for ******** ******, ******** ******,
********, ******* ** ***** ** ***** ******* ***** ***** *** ** *** *********:
*** ****** ** ************ *** ***** ** ******* ****, *** *********** ** ***
******* ********* ** ************** *** *** *** ** *** ********* ********* **
******** ** *** *********** ** *** ******* ****** ****** ** *** ***** **********
** ******* ********** ** ***; *** ***** ******** ** *** ******* ** *** **
******** *** ********** *********, *** ********, *******, *******,
**************, *********, ************, ****, ***, ********* ** ******** ** ***
******* ********** ***** ***** ***** *********** ******* ** * ********** ******
****** ** *** ***** ********** ** ******* ********** ** ***; ** *** ********
****** ** *** *** ******** ****** ****** ** *** ***** ********** ** *******
********** ** ***; ** *** ******* ******, *********, ***** **** ** *********
* Confidential Treatment Requested for information omitted and filed separately
with the SEC.
-14-
<PAGE> 18
************ ********* **** *** *** ** *** ******, *********, ***** ****,
********* ** **** *******, ********* ** *** ******* ** ********'* *******; **
*** ****** ** ********* ************ ***** ** *** *** ** *** ** *** **********
*********** ** *** ***********, **** ** *** ** *** ******* **** *** ********
******** ** **** *********. DOW shall give CUSTOMER notice in writing as soon as
practicable of any such claim or lawsuit and shall permit CUSTOMER to undertake
the defense thereof at CUSTOMER's expense.
15.5 DOW shall cooperate in such defense undertaken by CUSTOMER pursuant to
Section 15.4 by providing access to witnesses and evidence available to DOW. DOW
shall have the right to participate in any defense to the extent that, in its
judgment, DOW may be prejudiced thereby.
15.6 In any claim or suit in which DOW seeks indemnification by CUSTOMER, DOW
shall not settle, offer to settle or admit liability or damages in any such
claim or suit without the consent of CUSTOMER.
15.7 The provisions of this Article 15 shall survive any termination of this
Agreement.
ARTICLE 16 - INSURANCE
- ------------------------
16.1 CUSTOMER will, and will cause any pharmaceutical company with which it
associates in the commercialization of the Product to, procure and maintain
insurance in the following minimum amounts, at its own expense, at all times
while the Agreement is in effect:
(a) Workmen's Compensation insurance at statutory limits and
Employers' Liability Insurance at not less than $1,000,000 aggregate;
(b) Automobile Liability Insurance with a bodily injury, death, and
property damage combined single limit of $1,000,000; and
(c) Comprehensive General Liability Insurance (including contractual
liability, products, and completed operations) with a bodily injury, death,
and property damage combined single limit of $10,000,000 per occurrence.
The scope of this coverage is to be equivalent to standard ISO forms (e.g.,
1996 Commercial General Liability ISO form # CG 00 01 01 96, etc.) with no
limiting modifications.
16.2 CUSTOMER will, and will use best efforts to cause any pharmaceutical
company with which it associates in the commercialization of the Product to,
furnish DOW a certificate(s) from an insurance carrier (having a minimum AM Best
rating of B) showing all insurance set forth above. The certificate(s) will
include the following statement: "The insurance certified hereunder is
applicable to all contracts between The Dow Chemical Company and the Insured.
This insurance may be canceled or altered only after ten (10) days' written
notice to DOW." The insurance, and the certificate(s), will (1) name DOW
* Confidential Treatment Requested for information omitted and filed separately
with the SEC.
-15-
<PAGE> 19
(including DOW's officers, directors, employees, servants, affiliates, agents,
successors, and assigns) as additional insureds with respect to matters arising
from this Agreement, (2) provide that such insurance is primary to any liability
insurance carried by DOW, and (3) provide that underwriters and insurance
companies of CUSTOMER may not have any right of subrogation against DOW
(including DOW's officers, directors, employees, servants, affiliates, agents,
successors, and assigns) except in the event a claim results from DOW's gross
negligence or willful misconduct. The insurance will contain an ordinary
deductible. Failure of any of the terms and conditions of this Article 16 will
be considered a material breach under this Agreement.
ARTICLE 17 - DOW FACILITY
- ---------------------------
17.1 In DOW's performance of its obligations under this Agreement, DOW retains
the obligations to fully comply with the Operating Guidelines and all applicable
federal, state and local laws and regulations which are in effect at the time,
including FFDCA, and all applicable regulations promulgated by the FDA
thereunder. DOW retains the sole right and authority to make all decisions with
respect to the construction, maintenance and operation of DOW's Facility.
Without limiting DOW's obligations, CUSTOMER acknowledges that it may have
certain independent obligations in order for CUSTOMER to be in compliance with
laws, rules and regulations applicable to CUSTOMER.
17.2 The DOW Facility is registered with the FDA pursuant to ss.510 of FFDCA.
DOW agrees to maintain a valid FDA Establishment Number for the DOW Facility.
DOW shall keep and maintain records as required by the Operating Guidelines and
all applicable federal, state and local laws and regulations including, but not
limited to FFDCA. DOW shall prepare and submit all reports that DOW is required
by applicable federal, state and local laws and regulations to submit. DOW shall
provide CUSTOMER with a copy of any such reports. DOW shall promptly notify
CUSTOMER of any incidents involving the raw materials, packaging materials or
Product involving DOW's performance under this Agreement or of any actions or
inspections by the FDA relating to the manufacture of the Product. DOW retains
exclusive ownership and responsibility of all DOW Facility materials, reports
and records.
ARTICLE 18 - PRODUCT STEWARDSHIP
- -----------------------------------
18.1 CUSTOMER acknowledges that it has requested DOW to contract manufacture
Product for CUSTOMER pursuant to instructions and specifications provided to DOW
by CUSTOMER. CUSTOMER represents that it has used its own independent skill and
expertise in connection with the design, selection and use of the Product
(including other goods which incorporate Product as a component) and that it
possesses skill and expertise in the handling, storage, transportation,
treatment, use and disposal of the Product (including other goods which
incorporate Product as a component). CUSTOMER shall accept and agree to be bound
by appropriate product stewardship guidelines, including but not limited to: (a)
responsibility for providing Material Safety Data Sheets, (b) following safe
handling, use, selling, storage, transportation, treatment and disposal
practices
-16-
<PAGE> 20
(including special practices as CUSTOMER's use of the Product requires) and
instruct its employees, contractors (including DOW), agents and customers in
these practices (including the information contained in the most current
Material Safety Data Sheet), (c) taking appropriate action to avoid spills or
other dangers to persons, property or the environment, and (d) understanding and
complying (and has complied) with all applicable governmental statutes, rules,
regulations and ordinances including, without limitation, those promulgated by
the FDA and EPA.
18.2 DOW shall report to CUSTOMER, in writing and as promptly as practicable,
any complaints it receives concerning the Product, including any regulatory
complaints. CUSTOMER shall be responsible for handling such complaints, and DOW
shall cooperate to the extent reasonably requested by CUSTOMER. CUSTOMER shall
promptly disclose to DOW any information which becomes available to it relating
to alleged side effects, toxicity or other adverse effects allegedly caused by
the Product (including other goods which incorporate Product as a component).
ARTICLE 19 - FORCE MAJEURE
- ----------------------------
19.1 The performance of the party impacted by a Force Majeure Event, other than
for payment for Product already delivered, under this Agreement is delayed,
without liability, for the duration of a Force Majeure Event.
19.2 The party whose performance is affected by a Force Majeure Event shall give
prompt notice to the other party stating the details and expected duration of
the event. Once notice is given of a Force Majeure Event, the parties shall keep
each other apprised of the situation until the Force Majeure Event terminates or
this Agreement is terminated, whichever occurs first. Each party has full
management discretion in dealing with its own labor issues, and in determining
how and when to perform obligations (other than payment for work already
performed) under this Agreement when the other party is involved in a strike,
work stoppage or slowdown condition.
19.3 DOW may, during any period of shortage of raw materials (including energy
or other utilities), waste handling capability, labor, or Product due to force
majeure as defined in this Agreement, in DOW's discretion allocate its supply of
such raw materials (including energy or other utilities), waste handling
capability, labor and Product among the various uses therefor in any manner. DOW
shall have no obligation to obtain Product, or raw materials (including energy
or other utilities) from a third party in order to supply DOW's excused
contractual shortfall. The Product, or raw materials (including energy or other
utilities) obtained by DOW from a third party solely for DOW's internal use are
not subject to allocation.
-17-
<PAGE> 21
ARTICLE 20 - EARLY TERMINATION
- --------------------------------
20.1 Either party is entitled (without prejudice to its other rights and
remedies under this Agreement) to terminate this Agreement upon (a) written
notice at any time if the other party breaches a material obligation under this
Agreement and such breach has not be remedied within thirty (30) days after the
non-breaching party provides written notice of such breach to the breaching
party or (b) written notice by the party not affected by a Force Majeure Event
to the party affected by the Force Majeure Event if a Force Majeure Event lasts
for more than sixty (60) days. Further, either party shall be deemed to have
breached this Agreement in the event such party (a) voluntarily or involuntarily
enters a bankruptcy or similar proceeding; (b) passes a resolution for winding
up its business or a Court makes an order to that effect (otherwise than for the
purpose of amalgamation or reconstruction); or (c) a receiver is appointed in
respect of substantially all of its assets. ** *** ********, ** *** **********
*********** ******** ***** ** **** ********* ** ********, **** * ******** ******
** ************* *** ******* * ******* ** ** *** ******* ** ******** ** *******
*** *********** ***** **** ********* ***** ** *********** **** ****** ** ***
*******, **** **** *** ******* ** ******* ****** **** ***, *** ******* *****
**** ******** **** * **** ****** ********* **** *******. ** *** ******* ***
****** ** ******* **** ******* ****** ***** **** **** ** *** ******, **** **
**** ****, *** ** *** ********** **********, *** ****** *** *********** *****
**** *********, *********, *** *** ******* **, ********** ** ******** **
********.
20.2 DOW shall incur certain design, engineering and construction costs at the
DOW Facility in order to manufacture the Products. If this Agreement is
terminated by DOW, pursuant to Section 20.1, or by CUSTOMER, pursuant to Section
3.2, then, within thirty (30) days of such termination, CUSTOMER shall pay to
DOW an amount equal to the costs incurred by DOW and not already reimbursed by
CUSTOMER for design, engineering and construction at the DOW Facility up to and
including the date of the notification of termination; PROVIDED, HOWEVER, that
DOW shall use reasonable efforts to reduce such design, engineering and
construction costs. If this Agreement is terminated by CUSTOMER, pursuant to
Section 20.1, or by DOW, pursuant to Section 3.2, then CUSTOMER shall have no
obligation to pay for such design, engineering, and construction costs.
ARTICLE 21 - ASSIGNMENT
- -------------------------
This Agreement is not assignable or transferable by either party without the
prior written consent of the other party, such consent not to be unreasonably
withheld.
ARTICLE 22 - NOTICE
- ---------------------
Any notice to be given under this Agreement shall be in writing and shall be
deemed given when received and may be sent by mail, express courier or facsimile
to:
* Confidential Treatment Requested for information omitted and filed separately
with the SEC.
-18-
<PAGE> 22
If to CUSTOMER: If to DOW:
GelTex Pharmaceuticals, Inc. The Dow Chemical Company
Attn: Joseph Tyler Attn: Robert M. Strom
303 Bear Hill Road 1710 Building
Waltham, Massachusetts 02154 Midland, Michigan 48674
(617) 290-5890 (FAX) (517) 638-7003 (FAX)
Either party may change its location or facsimile number to receive notices upon
ten (10) days prior written notice.
ARTICLE 23 - PLANT VISITS
- ---------------------------
23.1 Subject to safety and confidentiality limitations, DOW shall permit
representatives of CUSTOMER to visit the DOW Facility for the purpose of
reviewing the manufacture and testing of the Product and related batch records
and of conducting compliance audits associated with GMPs and other FDA
regulations. Employees of CUSTOMER who enter onto DOW premises must comply with
DOW's safety, security and confidentiality requirements. CUSTOMER must give DOW
reasonable notice of any proposed visit to the DOW Facility and identify the
individuals who shall be in attendance. DOW is entitled to approve the
individuals who shall visit; however, DOW's approval may not be unreasonably
withheld. CUSTOMER may not designate contractors for such visits without the
prior written consent of DOW. All visits shall be during normal business hours
on Work Days. DOW may inspect any documents, vehicles, or containers entering or
leaving DOW premises. Each representative of CUSTOMER who visits the DOW
Facility must sign DOW's the Visitors Agreement in the form set forth in
Schedule 3 with a copy of the Visitor Agreement going to the representative and
CUSTOMER with DOW retaining the original.
23.2 During normal business hours on Work Days, DOW shall allow governmental
inspectors (such as inspectors from the FDA or EPA) acting pursuant to statutory
authority to inspect the DOW Facility in connection with the production of
Product and to review required documentation, provided that such inspectors
comply with DOW's safety, security and confidentiality requirements. All
governmental inspectors to conduct an inspection of DOW Facility shall be
subject to the reasonable approval of DOW prior to the inspection.
ARTICLE 24 - CONFIDENTIALITY OF INFORMATION
- -------------------------------------------
24.1 Each of DOW and CUSTOMER will receive Proprietary Information in order to
fulfill its respective obligations under this Agreement. Any Proprietary
Information should be marked as such. Information not marked as Proprietary
Information but which the party receiving it reasonably should recognize as
Proprietary Information shall be deemed
-19-
<PAGE> 23
to be Proprietary Information. Each party shall use reasonable efforts to retain
the other party's Proprietary Information in confidence and not disclose the
same to any third party nor use the same, except as expressly permitted.
Excepted from these obligations of confidence and non use is that information
which:
(a) is available, or becomes available, to the general public without
fault of the receiving party;
(b) was in the possession of the receiving party on a non-confidential
basis prior to receipt of the same from the disclosing party;
(c) is obtained by the receiving party without an obligation of
confidence from a third party who is rightfully in possession of such
information and is under no obligation of confidentiality to the disclosing
party;
(d) the receiving party is legally required to disclose; or
(e) is independently developed by the receiving party.
For the purpose of this Section 24.1, a specific item of Proprietary Information
shall not be deemed to be within the foregoing exceptions merely because it is
embraced by more general information in the public domain or in the possession
of the receiving party. In addition, any combination of features shall not be
deemed to be within the foregoing exceptions merely because individual features
are in the public domain or in the possession of the receiving party, but only
if the combination itself and its principle of operation are in the public
domain or in the possession of the receiving party.
24.2 Notwithstanding the provisions of 24.1(d), if the receiving party becomes
legally compelled to disclose any of the disclosing party's Proprietary
Information, the receiving party shall promptly advise the disclosing party of
such Proprietary Information in order that the disclosing party may seek a
protective order or such other remedy as the disclosing party may consider
appropriate in the circumstances. The receiving party shall disclose only that
portion of the disclosing party's Proprietary Information which it is legally
required to disclose.
24.3 All Proprietary Information in whatever form, other than Proprietary
Information consisting of DOW Program Technology (as defined in the Research
Service Agreement) or DOW Know-How licensed to CUSTOMER pursuant to the Research
Service Agreement, shall be returned to the disclosing party upon termination of
this Agreement, without retaining copies thereof except that one copy of all
such Proprietary Information may be retained by the other party's legal
department solely for the purposes of policing this Agreement. Upon termination
of this Agreement, CUSTOMER shall be permitted to retain copies of all DOW
Program Technology (as defined in the Research Service Agreement) and DOW
Know-How licensed to CUSTOMER pursuant to Research Service Agreement.
-20-
<PAGE> 24
24.4 The obligation of confidentiality under this Article 24 shall survive for
five (5) years following the expiration or termination of this Agreement.
24.5 The confidentiality provisions contained in this Article 24 shall supersede
the confidentiality provisions with regard to the Product contained in the
Secrecy Agreement between DOW and CUSTOMER dated April 24, 1996 (the "Secrecy
Agreement"); provided, however, that (a) the exchange of information between DOW
and CUSTOMER with regard to the Product prior to the Effective Date shall be
governed by the Secrecy Agreement and (b) the exchange of information on
products other than the Product shall continue to be governed by the Secrecy
Agreement.
ARTICLE 25 - EXPORT CONTROL OF TECHNICAL DATA
- -----------------------------------------------
The parties acknowledge their obligations to adhere to the United States export
laws and regulations, such as Export Administration Regulations, International
Traffic in Arms Regulations and regulations promulgated by the Office of Foreign
Assets Control and the parties agree to adhere to such laws and regulations.
ARTICLE 26 - TAXES
- ------------------
CUSTOMER shall pay to DOW (a) any applicable sales, use, gross receipts, or
value-added tax that is imposed as a result of, or measured by, the sales, and
(b) the amount of any and all other governmental taxes, duties and/or charges of
every kind, excluding any income tax imposed upon DOW, that is hereafter imposed
or increased, and which DOW may be required to pay with respect to the
production, sale or transportation of Product, with respect to any material used
in the manufacture thereof.
ARTICLE 27 - INDEPENDENT CONTRACTOR
- -------------------------------------
DOW is an independent contractor, with all the attendant rights and liabilities,
and not an agent or employee of CUSTOMER. The relationship between DOW and
CUSTOMER shall not constitute a partnership, joint venture or agency. Any
provision in this Agreement, or any action by CUSTOMER, which may appear to give
CUSTOMER the right to direct or control DOW in performing under this Agreement
means DOW shall follow the desires of CUSTOMER in results only. Neither party
shall have the authority to make any statements, representations or commitments
of any kind, or take any action, which shall be binding on the other, without
the prior written consent of the other party.
ARTICLE 28 - SEVERABILITY
- ---------------------------
If any provision of this Agreement or the application thereof to any person or
circumstance shall, for any reason, and to any extent, be held to be invalid or
unenforceable under applicable law, such provision shall be deemed limited or
modified to
-21-
<PAGE> 25
the extent necessary to make the same valid and enforceable under applicable
law. Any invalid or unenforceable provision shall be replaced with such new
provision which shall allow the parties to achieve the intended economic result
in a legally valid and effective manner.
ARTICLE 29 - NON-WAIVER OF DEFAULTS
- -------------------------------------
Any failure by either party at any time to enforce or require strict keeping and
performance of any of the terms or conditions of this Agreement shall not
constitute a waiver of such terms or conditions and shall not affect or impair
such terms or conditions in any way, or the right of either party at any time to
avail itself of such remedies as it may have for any breach or breaches of such
terms or conditions.
ARTICLE 30 - CREDIT
- ---------------------
If CUSTOMER fails to pay any invoice in accordance with the terms of this
Agreement, DOW may defer shipments, alter payment terms or cancel this
Agreement. If CUSTOMER's financial responsibility becomes unsatisfactory to DOW
and DOW deems itself insecure, DOW may accelerate the due date and demand
immediate payment on any outstanding invoice for Product, or may require cash
payments or satisfactory security for future deliveries. CUSTOMER agrees to pay
all costs and expenses, including reasonable attorney's fees, incurred by DOW in
the collection of any sum payable by CUSTOMER to DOW, or in the exercise of any
remedy.
ARTICLE 31 - GOVERNING LAW
- ----------------------------
The interpretation, validity and performance of this Agreement shall be governed
by Michigan law, including Michigan's adaptation of the Uniform Commercial Code,
without regard to Michigan's conflict-of-law rules.
ARTICLE 32 - HEADINGS
- -----------------------
The headings used in this Agreement are for the convenience of the reader and
are not intended to have any substantive meaning.
ARTICLE 33 - ENTIRE AGREEMENT
- -------------------------------
This Agreement constitutes the full understanding of the parties, and is a
final, complete and exclusive statement of the terms and conditions of their
agreement regarding the subject matter of this Agreement. All representations,
offers, and undertakings, of the parties made prior to the effective date of
this Agreement are merged in this Agreement. All amendments or modifications to
this Agreement must be in writing, identified as an Amendment to this Agreement
and signed by an authorized representative of each party.
-22-
<PAGE> 26
ARTICLE 34 - ARBITRATION
- ------------------------
34.1 Any Claim arising out of or relating to this Agreement, or any breach
thereof, including, without limitation, the validity of the provisions of this
Article 34, but excluding any Claim regarding technology or patents, shall be
settled in accordance with the Commercial Arbitration Rules of the American
Arbitration Association as amended and in effect January 1, 1990 (the "Rules"),
except as such Rules are modified by this Article 34.
34.2 Any arbitration pursuant to this Article 34 shall occur before a panel of
three arbitrators. Each of DOW and CUSTOMER shall select one arbitrator within
thirty (30) days of the notice of arbitration. The two arbitrators so selected
then shall have thirty (30) days to select a third arbitrator from a list of
potential arbitrators provided by the American Arbitration Association. If the
two arbitrators cannot select a third arbitrator within the thirty-day period,
then the American Arbitration Association shall select the third arbitrator. The
third arbitrator, regardless of how selected, shall chair the arbitration panel.
34.3 Any arbitration pursuant to this Article 34 shall take place at the offices
of the American Arbitration Association in New York, New York, or at such other
offices in New York, New York, as the American Arbitration Association may
stipulate. The arbitration shall be in English. Each party shall bear its
respective costs (including travel costs, witness and attorneys' fees) relating
to the arbitration. Each party shall bear an equal portion of the actual
arbitration costs including, but not limited to, arbitrator's fees and
administrative fees of the American Arbitration Association.
34.4 Not less than sixty (60) days from the date of any arbitration proceeding
under this Article 34, each party will provide to the other a list of the
witnesses that it intends to produce. The other party, at its expense, shall
have the opportunity to take the deposition of such witnesses prior to the
arbitration. In addition, not less than forty-five (45) days prior to the
arbitration date, each party shall provide to the other copies of the evidence
intended for use during the arbitration. Not less than ten (10) days before the
arbitration date, the parties may move the arbitration panel to exclude certain
evidence, setting forth the grounds for such request. The arbitrators shall
decide on any such motions in accordance with applicable law.
34.5 The arbitrators shall issue a written opinion, setting forth their decision
and its legal and factual basis. The opinion of the arbitrators shall be binding
upon the parties absent manifest error in the understanding of the facts or the
interpretation of applicable law.
34.6 Anything in this Article 34 to the contrary notwithstanding, prior to
initiating any arbitration, a party to this Agreement may seek an injunction,
temporary restraining order, or other similar temporary relief, from a court of
competent jurisdiction in order to protect the assets that are the subject of
dispute.
-23-
<PAGE> 27
The parties have caused this Agreement to be executed by their duly authorized
representatives.
GELTEX PHARMACEUTICALS, INC. THE DOW CHEMICAL COMPANY
By: /s/ Mark Skaletsky By: /s/ Michael D. Parker
- ------------------------------------ ---------------------------------
Name: Mark Skaletsky Name: Michael D. Parker
- ------------------------------------ ---------------------------------
Title: President Title: Executive Vice President
- ------------------------------------ ---------------------------------
Date: April 23, 1997 Date: April 23, 1997
- ------------------------------------ ---------------------------------
-24-
<PAGE> 28
SCHEDULE 1
----------
PRODUCT SPECIFICATIONS
----------------------
TEST METHOD SPECIFICATION
- ---- ------ -------------
********** ******** *************************
**** ******** **************************
********* ******* ***** ******** **** ** ****** ** *********
******** ********* ***** * ***
**********
**** ** ****** ********** *****
******** ********** ******** * ** ***
******** *************** ******** * * ***
******* ********* ******** * **** *****************
***** ****** **** ***** * ******
******* ** ******** **** ***** * ****
** ** ** ******** ******** **************
******** **** ******** *** * * **
**** ******** **** ***** **
******** ***** * *** ** ***********
***** ******* ** ******** ******** ***** ** *****
******** ***** ******** *** ** ***
********* ***** **** **** * *** *** *** ****
*** ** ********** * *** ***
************ ** ********** * ** ***
*** ******* **** ***** ** ** **********
* Confidential Treatment Requested for information omitted and filed separately
with the SEC.
<PAGE> 29
SCHEDULE 2
----------
OPERATING GUIDELINES
--------------------
Operating Guidelines shall be those contained in the Chemical Methods Control
section of the NDA.
<PAGE> 30
SCHEDULE 3
----------
VISITORS AGREEMENT
------------------
I, __________________, a citizen of _____________________________, in
consideration of my employment by GelTex Pharmaceuticals, Inc. ("Employer"), and
in consideration for admittance to the premises of and/or access to the
technical and business information of The Dow chemical Company ("Dow"), agree as
follows:
1. I will proceed directly to the location to which I am expected by CUSTOMER,
and, when finished, will promptly leave the Dow premises by my original
point of entry or by the most reasonable direct route;
2. I will not bring any cameras or video recording devices onto Dow premises.
I will not take pictures, make video recordings or make drawings or other
representations of Dow facilities unless authorized by Dow in writing to do
so;
3. I will not remove from Dow any documents or property of any kind unless
authorized by Dow to do so and will return any such information to Dow when
requested to do so;
4. I will keep as confidential and secret all technical and business
information concerning Dow and its operations which I obtain by observation
or other means as a result of my presence on Dow's premises; I will not
publish or disclose to any third party any information I have received from
Dow without the prior written permission of Dow;
5. I understand that the obligations of confidence do not apply to any
information which is or becomes known to the public without my fault, or
which is acquired by me without an obligation of confidence from a third
party having a right to disclose the information;
6. I will hold Dow harmless for any injury, including death or disease, to
myself or any damage to my property while on Dow's premises unless such
injury or damage is caused by Dow's sole negligence;
7. I will, upon request, surrender to Dow's Security any pass issued to me; in
addition, I understand that any pass issued to me is not transferable and I
agree I will not allow any other person to use it;
8. I will not knowingly export, directly or indirectly, any Dow proprietary
Technology or software, or the direct product of such technology or
software, in violation of the provisions of the U. S. Export Administration
Regulations 15 CFR Parts 768-799;
9. I understand that the terms of this Agreement are legally enforceable
against me by Dow;
10. I understand that Dow reserves the right to inspect any document, vehicle
or container entering or leaving its premises;
11. I understand and acknowledge that Dow may direct (or cause to be directed)
me to leave Dow's premises (either temporarily or permanently) at any time
for any reason;
12. I understand that I must become familiar with and follow any applicable Dow
Safety Rules as well as any applicable federal or state safety laws or
regulations;
13. I understand that my obligations under this Agreement will survive the
termination of any particular assignment and my employment with Employer;
14. I understand that alcohol or illegal drugs are prohibited from Dow's
premises; and,
15. I understand and acknowledge that I am not an employee of Dow and am
therefore not entitled to any benefits from Dow.
Date: Signed:
---------------- -------------------------------
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JAN-01-1997
<PERIOD-END> MAR-31-1997
<CASH> 15,567
<SECURITIES> 52,597
<RECEIVABLES> 172
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 69,506
<PP&E> 3,900
<DEPRECIATION> 1,908
<TOTAL-ASSETS> 72,034
<CURRENT-LIABILITIES> 2,632
<BONDS> 0
0
0
<COMMON> 135
<OTHER-SE> 68,947
<TOTAL-LIABILITY-AND-EQUITY> 72,034
<SALES> 0
<TOTAL-REVENUES> 140
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 7,053
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 11
<INCOME-PRETAX> (5,958)
<INCOME-TAX> 0
<INCOME-CONTINUING> (5,958)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (5,958)
<EPS-PRIMARY> (.44)
<EPS-DILUTED> (.44)
</TABLE>
